Edward Garon
MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Sessions

Register
General Session

Plenary: Biomarkers Beyond Boundaries: Opportunities and Challenges of Biology Crossing Histologic Categorization

Saturday, March 14, 2026
8:10 AM - 8:55 AM
General Session

Case-Based Treatment Strategies in Lung Cancers

Saturday, March 14, 2026
11:10 AM - 11:55 AM
General Session

Resectable Lung Cancer: Neoadjuvant Only vs Perioperative Therapy

Saturday, March 14, 2026
4:25 PM - 5:10 PM
General Session

Management of Oligo-Remnant Metastatic Lung Cancer: Systemic Therapy Alone vs Systemic Therapy Plus Local Ablation

Sunday, March 15, 2026
11:10 AM - 11:55 AM
General Session

Treatment After Progression on Chemoimmunotherapy in Lung Cancer: Continuing Standard Cytotoxic Therapy vs Transitioning to Alternative Approaches

Sunday, March 15, 2026
2:55 PM - 3:40 PM
General Session

Resectable Lung Cancer: Neoadjuvant Only vs Perioperative Therapy

Saturday, September 26, 2026
10:05 AM - 10:50 AM
General Session

First-Line Strategies in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: Monotherapy Approaches vs Combination Approaches

Saturday, September 26, 2026
3:30 PM - 4:15 PM
General Session

Management of Oligo-Remnant Metastatic Lung Cancer: Systemic Therapy Alone vs Systemic Therapy Plus Local Ablation

Sunday, September 27, 2026
10:05 AM - 10:50 AM
General Session

Treatment After Progression on Chemoimmunotherapy in Non-Small Cell Lung Cancer: Continuing Standard Cytotoxic Therapy vs Transitioning to Alternative Approaches

Sunday, September 27, 2026
3:30 PM - 4:15 PM
Back to top